Novel directions for diabetes mellitus drug discovery
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Diabetes mellitus impacts almost 200 million individuals worldwide and leads to debilitating complications. New avenues of drug discovery must target the underlying cellular processes of oxidative stress, apoptosis, autophagy, and inflammation that can mediate multi-system pathology during diabetes mellitus. AREAS COVERED: The authors examine the novel directions for drug discovery that involve: the β-nicotinamide adenine dinucleotide (NAD(+)) precursor nicotinamide, the cytokine erythropoietin, the NAD(+)-dependent protein histone deacetylase SIRT1, the serine/threonine-protein kinase mammalian target of rapamycin (mTOR), and the wingless pathway. Furthermore, the authors present the implications for the targeting of these pathways that oversee gluconeogenic genes, insulin signaling and resistance, fatty acid beta-oxidation, inflammation, and cellular survival. EXPERT OPINION: Nicotinamide, erythropoietin, and the downstream pathways of SIRT1, mTOR, forkhead transcription factors, and wingless signaling offer exciting prospects for novel directions of drug discovery for the treatment of metabolic disorders. Future investigations must dissect the complex relationship and fine modulation of these pathways for the successful translation of robust reparative and regenerative strategies against diabetes mellitus and the complications of this disorder.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cantó, C., Houtkooper, R. H., Pirinen, E., Youn, D. Y., Oosterveer, M. H., Cen, Y., Fernandez-Marcos, P. J., Yamamoto, H., Andreux, P. A., Cettour-Rose, P., et al. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2012.04.022 · Cited by 1,238 · cited 1×
“Although other NAD precursors similar to nicotinamide, such as nicotinamide riboside, can increase NAD levels and activate SIRT1 resulting in protection against high-fat diet-induced metabolic abnormalities [115], NAD precursors such as nicotinamide also can lead to cellular energy depletion that is detrimental to cel…”
Exercise-induced BCL2-regulated autophagy is required for muscle glucose homeostasis
He, C., Bassik, M. C., Moresi, V., Sun, K., Wei, Y., Zou, Z., An, Z., Loh, J., Fisher, J., Sun, Q., et al. (2012) · Nature · doi:10.1038/nature10758 · Cited by 1,136 · cited 1×
“Exercise in mice has been shown to initiate autophagy and regulate glucose homeostasis [14].”
SIRT1 Improves Insulin Sensitivity under Insulin-Resistant Conditions by Repressing PTP1B
Sun, C., Zhang, F., Ge, X., Yan, T., Chen, X., Shi, X., & Zhai, Q. (2007) · Cell Metabolism · doi:10.1016/j.cmet.2007.08.014 · Cited by 766
Sirt1 Regulates Insulin Secretion by Repressing UCP2 in Pancreatic β Cells
Bordone, L., Motta, M. C., Picard, F., Robinson, A., Jhala, U. S., Apfeld, J., McDonagh, T., Lemieux, M., McBurney, M., Szilvasi, A., et al. (2005) · PLoS Biology · doi:10.1371/journal.pbio.0040031 · Cited by 715 · cited 1×
“SIRT1 also can stimulate glucose-dependent insulin secretion from pancreatic b cells by repressing the uncoupling protein (UCP) gene UCP2 [72].”
Gale, E. A. (2004) · The Lancet · doi:10.1016/s0140-6736(04)15786-3 · Cited by 534 · cited 1×
“These observations fall in line with the need to determine effective and safe concentrations of nicotinamide, since prior clinical trails that examined nicotinamide application to prevent Type I DM onset did not identify an effective concentration [48].”
SIRT1 Negatively Regulates the Mammalian Target of Rapamycin
Ghosh, H. S., McBurney, M., & Robbins, P. D. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009199 · Cited by 397
OutFOXOing disease and disability: the therapeutic potential of targeting FoxO proteins
Maiese, K., Chong, Z. Z., & Shang, Y. C. (2008) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2008.03.002 · Cited by 182 · cited 2×
“SIRT1 also may rely upon the regulation of FoxO transcription factors to protect against inflammation, to promote b-cell function during DM, and to maintain endothelial survival during oxidative stress [7,83].”
Self-citationShedding new light on neurodegenerative diseases through the mammalian target of rapamycin
Chong, Z. Z., Shang, Y. C., Wang, S., & Maiese, K. (2012) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2012.08.001 · Cited by 119 · cited 1×
“4 Serine/threonine-protein kinase mTOR Metabolic signaling that is mediated through Akt not only relies upon pathways with nicotinamide, EPO, and SIRT1, but also controls metabolic cell pathways through the serine/ threonine protein kinase mTOR that has other alternative names including mechanistic target of rapamycin…”
Self-citationMammalian target of rapamycin signaling in diabetic cardiovascular disease
Chong, Z., & Maiese, K. (2012) · Cardiovascular Diabetology · doi:10.1186/1475-2840-11-45 · Cited by 95 · cited 4×
“Loss of mTOR signaling with inhibition of p70S6K can result in hypoinsulinemia, glucose intolerance, insulin insensitivity to glucose secretion, and a decrease in pancreatic b-cell size [9,89].”
InfluentialSelf-citationCardiovascular Disease and mTOR Signaling
Chong, Z. Z., Shang, Y. C., & Maiese, K. (2011) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2012.04.005 · Cited by 87
Self-citation
Cited by
Tebay, L. E., Robertson, H., Durant, S. T., Vitale, S. R., Penning, T. M., Dinkova-Kostova, A. T., & Hayes, J. D. (2015) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2015.06.021 · Cited by 837
“Both mTORC1 and mTORC2 have been shown to be dysregulated during the development and progression of DM through independent signaling mechanisms; mTORC1 plays a role in the initiation of DM with inhibition of the transcriptional regulator p70S6K, an mTORC1 target, leading to glucose intolerance, loss of insulin sensiti…”
Mechanistic Insight into Oxidative Stress-Triggered Signaling Pathways and Type 2 Diabetes
Singh, A., Kukreti, R., Saso, L., & Kukreti, S. (2022) · Molecules · doi:10.3390/molecules27030950 · Cited by 325
Chen Shang, Y., Zhong Chong, Z., Wang, S., & Maiese, K. (2013) · Current Neurovascular Research · doi:10.2174/156720213804806007 · Cited by 61
“The later apoptotic phase involving the cleavage of genomic DNA into fragments usually does not allow for the repair or recovery of cells [41, 52, 53].”
BackgroundSelf-citationWang, S., Zhong Chong, Z., Chen Shang, Y., & Maiese, K. (2013) · Current Neurovascular Research · doi:10.2174/156720213804805945 · Cited by 58
Self-citation
Metadata
- Authors
- Maiese, K., Chong, Z. Z., Shang, Y. C., & Wang, S.
- Venue
- Expert Opinion on Drug Discovery
- Publisher
- Informa Healthcare
- Published
- 2012-10-24
- Volume
- 8
- Issue
- 1
- Pages
- 35-48
- ISSN
- 1746-0441 (ISSN-L)
- 1746-045X
- OpenAlex
- W2020287090
- Cited by
- 71
- References
- 14
- FWCI
- 3.63
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Novel directions for diabetes mellitus drug discovery. https://app.cochat.ai/papers/10.1517/17460441.2013.736485
- The paper
- Maiese, K., Chong, Z. Z., Shang, Y. C., & Wang, S. (2013). Novel directions for diabetes mellitus drug discovery. Expert Opinion on Drug Discovery. https://doi.org/10.1517/17460441.2013.736485
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.